Axsome Therapeutics, Inc. 10-Q filing
Filed 2026-05-04 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001193125-26-204274
- Form type
- 10-Q
- CIK
- 0001579428
- Primary document
- https://www.sec.gov/Archives/edgar/data/1579428/000119312526204274/axsm-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Axsome Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $191.2M | - | - |
| Operating Income | $-63.4M | - | - |
| Net Income | $-64.5M | - | - |
| Eps Basic | -1.26 | - | - |
| Eps Diluted | -1.26 | - | - |
| Cash And Equivalents | $305.1M | - | - |
| Total Assets | $713.6M | - | - |
| Total Liabilities | $659.0M | - | - |
| Shareholders Equity | $54.6M | - | - |
| Operating Cash Flow | $-20.7M | - | - |
| Capital Expenditures | $121,000 | - | - |